Company Sirnaomics Ltd.

Equities

2257

KYG2050P1028

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 09:08:20 14/05/2024 BST			5-day change	1st Jan Change
7.65 ^HKD	+5.37%		+3.24%	-78.63%

05-10	Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director	CI
04-17	Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment	MT

Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.

Number of employees: 145

Managers	Title	Age	Since
Patrick Lu CEO	Chief Executive Officer	68	14/10/20
Wing Kei Yip DFI	Director of Finance/CFO	39	30/09/18
David Evans CTO	Chief Tech/Sci/R&D Officer	61	11/07/21
Francois Lebel CTO	Chief Tech/Sci/R&D Officer	72	27/07/23
Dmitry Samarsky CTO	Chief Tech/Sci/R&D Officer	57	-
Yong Xiang Wang BRD	Director/Board Member	71	31/12/19
Xiao Chang Dai BRD	Director/Board Member	61	24/01/21
John Buergenthal HRO	Human Resources Officer	-	-
Zhi Feng Long PRN	Corporate Officer/Principal	62	-
Ting Cheung Leung SEC	Corporate Secretary	41	-

Members of the board	Title	Age	Since
Feng Mao Hua BRD	Director/Board Member	56	30/11/21
Patrick Lu CEO	Chief Executive Officer	68	14/10/20
David Evans CTO	Chief Tech/Sci/R&D Officer	61	11/07/21
Cheung Hoi Yu BRD	Director/Board Member	69	30/06/21
Mo Han Shing BRD	Director/Board Member	68	-
Jian Kang Zhang BRD	Director/Board Member	67	11/07/21
Xiao Chang Dai BRD	Director/Board Member	61	24/01/21
Min Cong Huang BRD	Director/Board Member	35	24/01/21
Mo Nin Ung BRD	Director/Board Member	55	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	87,638,480	71,197,165 ( 81.24 %)	0	81.24 %

Name	Equities	%	Valuation
Patrick Lu 10.60 %	9,289,082	10.60 %	8 M $
Shenzhen Qianhai Xuanshi Fund Management Co. Ltd. 5.208 %	4,564,495	5.208 %	4 M $
Xiao Chang Dai 1.904 %	1,668,757	1.904 %	1 M $
Min Cong Huang 0.8644 %	757,551	0.8644 %	666 387 $
Bosera Asset Management Co., Ltd. 0.7228 %	633,450	0.7228 %	557 221 $
David Evans 0.0869 %	76,162	0.0869 %	66 997 $
Michael Vance Molyneaux 0.000000 %	0	0.000000 %	- $

Sirnaomics Ltd.

46/F, Hopewell Centre 183 Queen's Road East

, Hong Kong

http://www.sirnaomics.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9792 USD

Average target price

9.231 USD

Spread / Average Target

+842.69%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SIRNAOMICS LTD.	-78.63%	80.68M
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	105B
BIONTECH SE	-12.56%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.86%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+5.10%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.45B

Bio Therapeutic Drugs